Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 111

Sort by

Sort Order Select

Journal Articles

Clonal Phylogeny and Evolution of Critical Cytogenetic Aberrations in Multiple Myeloma at Single Cell Level

Yuting Yan, Xiaoqi Qin, Lanting Liu, Shuhui Deng, MD, Jiahui Liu, Huishou Fan, Weiwei Sui, MD, Fu Mingwei, MD, Xue-Han Mao, MD, Zhen Yu, MD, Dehui Zou, MD, Lugui Qiu, MD, Gang An, MD PhD

Blood (2020) 136 (Supplement 1): 43–44.

https://doi.org/10.1182/blood-2020-143447

Published: 2020

Journal Articles

Novel Insight into Multi-Hit Multiple Myeloma Based on "Two-Hit" Theory of Cancer Causation

Chenxing Du, MD, Xue-Han Mao, MD, Jiahui Liu, Huishou Fan, Weiwei Sui, MD, Shuhui Deng, MD, Shuhua Yi, MD, Wenyang Huang, Yan Xu, Chengwen Li, Jiawei Zhao, Dehui Zou, MD, Yaozhong Zhao, Jianxiang Wang, MD, Lugui Qiu, MD, Gang An, MD PhD

Blood (2020) 136 (Supplement 1): 47–48.

https://doi.org/10.1182/blood-2020-140909

Published: 2020

Journal Articles

Igh Translocation with Undefined Partners Is Associated with Superior Outcome in Multiple Myeloma Patients

Xue-Han Mao, MD, Yan Xu, MD, Yuting Yan, Junling Zhuang, MD PhD, Huishou Fan, Weiwei Sui, Jiahui Liu, Shuhui Deng, MD, Shuhua Yi, MD, Lugui Qiu, MD, Gang An

Blood (2020) 136 (Supplement 1): 12.

https://doi.org/10.1182/blood-2020-140225

Published: 2020

Journal Articles

Anti-CD19 CAR T-Cell (CNCT19) Infusion Following HDT/ASCT Is Safe and Effective in Patients with Relapsed/Refractory Large B-Cell Lymphoma

Wei Liu, Wenyang Huang, Ryu Lv, Shuhui Deng, MD, Shuhua Yi, MD, Huimin Liu, Lulu Lv, Lugui Qiu, MD, Dehui Zou, MD, Jianxiang Wang, MD

Blood (2020) 136 (Supplement 1): 2.

https://doi.org/10.1182/blood-2020-139351

Published: 2020

Journal Articles

Earlier Use of Zanubrutinib Monotherapy in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Is Associated with Greater Efficacy: A Pooled Analysis from 3 Studies

Blood (2020) 136 (Supplement 1): 36–37.

https://doi.org/10.1182/blood-2020-136236

Published: 2020

Journal Articles

Safety and Efficacy of the Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with WaldenstrC6m Macroglobulinemia from a Phase 2 Trial

Gang An, MD PhD, Daobin Zhou, MD PhD, Weili Zhao, MD PhD, Keshu Zhou, MD PhD, Jianyong Li, MD PhD, Jianfeng Zhou, MD PhD, Liping Xie, MD PhD, Jie Jin, MD PhD, Liye Zhong, MD PhD, Lingzhi Yan, MD PhD, Haiyi Guo, MD, Chenmu Du, MD, Jane Huang, MD, William Novotny, MD, Jinhua Zhong, PhD, Lugui Qiu, MD

Blood (2020) 136 (Supplement 1): 42–43.

https://doi.org/10.1182/blood-2020-136783

Published: 2020

Journal Articles

Minimal Residual Disease Assessment Is an Independent Prognostic Factor in Splenic Marginal Zone Lymphoma

Ryu Lv, Yi Wang, Tingyu Wang, Xiong Wenjie, Huijun Wang, Yuting Yan, Qi Wang, Wei Liu, Gang An, MD PhD, Wenyang Huang, Weiwei Sui, MD, Yan Xu, MD, Zhen Yu, MD, Dehui Zou, MD, Jianxiang Wang, MD, Lugui Qiu, MD, Shuhua Yi, MD

Blood (2020) 136 (Supplement 1): 2.

https://doi.org/10.1182/blood-2020-138592

Published: 2020

Journal Articles

Waldenström's Macroglobulinaemia in the Modern Era: Real World Outcomes and Prognostication across 35 Chinese Academic Hospitals

Blood (2020) 136 (Supplement 1): 5–6.

https://doi.org/10.1182/blood-2020-134785

Published: 2020

Journal Articles

Multiple Myeloma Cell Defects Erythropoiesis and Results Anemia Via High Level of CCL3 in Bone Marrow Microenvironment

Lanting Liu, Zhen Yu, MD, Hui Cheng, Weiwei Sui, Shuhui Deng, MD, Xiaojing Wei, Chenxing Du, MD, Wenyang Huang, Gang An, Wen Zhou, PhD, Tao Cheng, Lugui Qiu, MD, Mu Hao

Blood (2020) 136 (Supplement 1): 55.

https://doi.org/10.1182/blood-2020-139006

Published: 2020

Journal Articles

Development and Analysis of a Weighed Prognostic Model in Newly Diagnosed Multiple Myeloma Patients

Xue-Han Mao, MD, Yan Xu, MD, Yuting Yan, Jiahui Liu, Huishou Fan, Weiwei Sui, Shuhui Deng, MD, Chenxing Du, MD, Dehui Zou, MD, Lugui Qiu, MD, Gang An

Blood (2020) 136 (Supplement 1): 47–48.

https://doi.org/10.1182/blood-2020-140464

Published: 2020

Journal Articles

Safety and Efficacy of GBC/GBM Conditioning Regimen Followed By Autologous Stem Cell Transplantation in Lymphoid Malignancies

Huimin Liu, Wei Liu, Ru Li, Wenyang Huang, Shuhua Yi, MD, Ryu Lv, Shuhui Deng, MD, Gang An, Lugui Qiu, MD, Dehui Zou, MD

Blood (2020) 136 (Supplement 1): 14–15.

https://doi.org/10.1182/blood-2020-138774

Published: 2020

Journal Articles

Prognostic Impact of Hyperdiploidy on Multiple Myeloma in the Era of New Agents

Yi Wang, Jing Zhuang, Gang An, MD PhD, Xue-Han Mao, MD, Chenxing Du, MD, Jiahui Liu, Huishou Fan, Shuhui Deng, MD, Yan Xu, MD, Weiwei Sui, Lugui Qiu, MD

Blood (2020) 136 (Supplement 1): 20.

https://doi.org/10.1182/blood-2020-141188

Published: 2020

Journal Articles

The Prognostic Impact of Dynamic Changes of Genetic Risk Stratification in Multiple Myeloma

Blood (2020) 136 (Supplement 1): 1–3.

https://doi.org/10.1182/blood-2020-139345

Published: 2020

Journal Articles

The Real-Word Treatment Outcome of Symptomatic Lymphoplasmacytic Lymphoma/ Waldenström Macroglobulinemia in Chinese Patients

Xiong Wenjie, Shuhua Yi, MD, Tingyu Wang, Huimin Liu, Rui Lv, Wei Liu, Dehui Zou, MD, Lugui Qiu, MD

Blood (2020) 136 (Supplement 1): 41–42.

https://doi.org/10.1182/blood-2020-139145

Published: 2020

Journal Articles

The Cytogenetic Aberrations of Lymphoplasmacytic Lymphoma/ Waldenström's Macroglobulinemia in China

Xiong Wenjie, Shuhua Yi, MD, Huimin Liu, Tingyu Wang, Wei Liu, Dehui Zou, MD, Lugui Qiu, MD

Blood (2020) 136 (Supplement 1): 35–36.

https://doi.org/10.1182/blood-2020-139184

Published: 2020

Journal Articles

The Relative Risk of Prognostic Factors of Age Stratified Multiple Myeloma

Chenxing Du, MD, Yi Wang, Xue-Han Mao, MD, Yuting Yan, Jiahui Liu, Huishou Fan, Yan Xu, Weiwei Sui, MD, Shuhui Deng, MD, Fu Mingwei, MD, Chengwen Li, Jiawei Zhao, Shuhua Yi, MD, Dehui Zou, MD, Yaozhong Zhao, Lugui Qiu, MD, Gang An, MD PhD

Blood (2020) 136 (Supplement 1): 26–27.

https://doi.org/10.1182/blood-2020-140718

Published: 2020

Journal Articles

A Novel CD138-Targeting Monoclonal Antibody Induces Potent Myeloma Killing and Further Synergizes with IMiDs or Bortezomib in in Vitro and In Vivo Preclinical Models of Human Multiple Myeloma

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-136824

Published: 2020

Journal Articles

Thalidomide Plus Prednisone and Methotrexate for Symptomatic Large Granular Lymphocyte Leukemia: A Prospective, Single-Center, Pilot Study

Shuhua Yi, MD, Jun Du, Ying Yu, Yang Jiao, Yi Wang, Huijun Wang, Tingyu Wang, Rui Lv, Wei Liu, Wenjie Xiong, PhD, Huimin Liu, Wenyang Huang, Dehui Zou, MD, Gang An, Yaozhong Zhao, Jianxiang Wang, MD, Lugui Qiu, MD

Blood (2020) 136 (Supplement 1): 23–24.

https://doi.org/10.1182/blood-2020-139481

Published: 2020

Journal Articles

Genomic and Transcriptomic Profiling Reveals Distinct Subsets Associated with Outcomes in Mantle Cell Lymphoma

Blood (2020) 136 (Supplement 1): 28–29.

https://doi.org/10.1182/blood-2020-139955

Published: 2020

Journal Articles

The Risk of Hepatitis B Reactivation Is Controllable in Patients with Concomitant Hepatitis B Virus Infection during Chimeric Antigen Receptor T-Cell Therapy

Wei Liu, Rui Lv, Wenyang Huang, Hong Liu, Shuhui Deng, MD, Shuhua Yi, MD, Lulu Lv, Jianxiang Wang, MD, Lugui Qiu, MD PhD, Dehui Zou, MD

Blood (2019) 134 (Supplement_1): 2913.

https://doi.org/10.1182/blood-2019-126635

Published: 2019

NARROW

Clonal Phylogeny and Evolution of Critical Cytogenetic Aberrations in Multiple Myeloma at Single Cell Level

Novel Insight into Multi-Hit Multiple Myeloma Based on "Two-Hit" Theory of Cancer Causation

Igh Translocation with Undefined Partners Is Associated with Superior Outcome in Multiple Myeloma Patients

Anti-CD19 CAR T-Cell (CNCT19) Infusion Following HDT/ASCT Is Safe and Effective in Patients with Relapsed/Refractory Large B-Cell Lymphoma

Earlier Use of Zanubrutinib Monotherapy in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Is Associated with Greater Efficacy: A Pooled Analysis from 3 Studies

Safety and Efficacy of the Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with WaldenstrC6m Macroglobulinemia from a Phase 2 Trial

Minimal Residual Disease Assessment Is an Independent Prognostic Factor in Splenic Marginal Zone Lymphoma

Waldenström's Macroglobulinaemia in the Modern Era: Real World Outcomes and Prognostication across 35 Chinese Academic Hospitals

Multiple Myeloma Cell Defects Erythropoiesis and Results Anemia Via High Level of CCL3 in Bone Marrow Microenvironment

Development and Analysis of a Weighed Prognostic Model in Newly Diagnosed Multiple Myeloma Patients

Safety and Efficacy of GBC/GBM Conditioning Regimen Followed By Autologous Stem Cell Transplantation in Lymphoid Malignancies

Prognostic Impact of Hyperdiploidy on Multiple Myeloma in the Era of New Agents

The Prognostic Impact of Dynamic Changes of Genetic Risk Stratification in Multiple Myeloma

The Real-Word Treatment Outcome of Symptomatic Lymphoplasmacytic Lymphoma/ Waldenström Macroglobulinemia in Chinese Patients

The Cytogenetic Aberrations of Lymphoplasmacytic Lymphoma/ Waldenström's Macroglobulinemia in China

The Relative Risk of Prognostic Factors of Age Stratified Multiple Myeloma

A Novel CD138-Targeting Monoclonal Antibody Induces Potent Myeloma Killing and Further Synergizes with IMiDs or Bortezomib in in Vitro and In Vivo Preclinical Models of Human Multiple Myeloma

Thalidomide Plus Prednisone and Methotrexate for Symptomatic Large Granular Lymphocyte Leukemia: A Prospective, Single-Center, Pilot Study

Genomic and Transcriptomic Profiling Reveals Distinct Subsets Associated with Outcomes in Mantle Cell Lymphoma

The Risk of Hepatitis B Reactivation Is Controllable in Patients with Concomitant Hepatitis B Virus Infection during Chimeric Antigen Receptor T-Cell Therapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only